isoproterenol has been researched along with valsartan in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 10 (52.63) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Blanc, J; Elghozi, JL; Lambert, G | 2 |
| Barki-Harrington, L; Luttrell, LM; Rockman, HA | 1 |
| Bayir, Y; Halici, Z; Keles, MS; Suleyman, H | 1 |
| Adams, F; Birkenfeld, AL; Engeli, S; Jordan, J; Schroeder, C | 1 |
| Arya, DS; Bharti, S; Goyal, S; Sahoo, KC; Sharma, AK | 1 |
| Chen, J; Huang, L; Le, X; Meng, J; Tang, Y; Wang, M; Wu, P; Yu, P | 1 |
| Albayrak, A; Bayir, Y; Ferah, I; Halici, Z; Kabalar, E; Karakus, E; Keles, MS; Keles, O; Unal, B | 1 |
| Al-Mazroua, HA; Al-Rasheed, NM; Korashy, HM | 1 |
| Akhtar, M; Akhtar, MS; Hassan, MQ; Imran, M; Najmi, AK; Rahman, O | 1 |
| Akagi, S; Ito, H; Kondo, M; Miura, D; Miyoshi, T; Nakamura, K; Ohno, Y; Saito, Y; Yoshida, M | 1 |
| Ates, B; Colak, C; Ermis, N; Ozhan, O; Parlakpinar, H; Ulutas, Z; Vardi, N | 1 |
| Ali, A; Alkhoury, J; Björnson, E; Boren, J; Espinosa, A; Gan, LM; Henricsson, M; Levin, M; Omerovic, E; Oras, J; Redfors, B | 1 |
| Duan, X; Feng, Y; Wang, J; Yuan, J; Zhou, J | 1 |
| Afzal, O; Akhtar, MS; Altamimi, A; Hassan, MZ; Hassan, Q; Mohammad, AAS; Sharma, AK; Tabassum, F | 1 |
1 review(s) available for isoproterenol and valsartan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
18 other study(ies) available for isoproterenol and valsartan
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Endogenous renin and related short-term blood pressure variability in the conscious rat.
Topics: Adrenergic beta-Agonists; Animals; Antihypertensive Agents; Aorta, Abdominal; Blood Pressure; Carotid Arteries; Catecholamines; Heart Rate; Infusions, Intra-Arterial; Isoproterenol; Male; Rats; Rats, Wistar; Renin; Signal Processing, Computer-Assisted; Tetrazoles; Valine; Valsartan | 2000 |
[Activation of the renin-angiotensin system and blood pressure variability in rats].
Topics: Adrenergic beta-Agonists; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Carotid Arteries; Catecholamines; Catheters, Indwelling; Femoral Artery; Fourier Analysis; Heart Rate; Infusions, Intravenous; Isoproterenol; Male; Rats; Rats, Wistar; Receptors, Adrenergic, beta; Renin; Renin-Angiotensin System; Signal Processing, Computer-Assisted; Tachycardia; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2000 |
Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Binding, Competitive; Cell Line; Cells, Cultured; COS Cells; Female; Heart Rate; Heterotrimeric GTP-Binding Proteins; Humans; Isoproterenol; Macromolecular Substances; Mice; Mice, Inbred C57BL; Myocardial Contraction; Myocytes, Cardiac; Propranolol; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, beta; Receptors, Angiotensin; Signal Transduction; Tetrazoles; Valine; Valsartan | 2003 |
Investigation of effects of Lacidipine, Ramipril and Valsartan on DNA damage and oxidative stress occurred in acute and chronic periods following isoproterenol-induced myocardial infarct in rats.
Topics: Animals; Antihypertensive Agents; Biomarkers; Dihydropyridines; DNA Damage; Guanine; Isoproterenol; Myocardial Infarction; Nitric Oxide; Oxidative Stress; Ramipril; Rats; Tetrazoles; Valine; Valsartan | 2009 |
Metabolic actions could confound advantageous effects of combined angiotensin II receptor and neprilysin inhibition.
Topics: Adipocytes; Adrenergic beta-Agonists; Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Biphenyl Compounds; Cells, Cultured; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Humans; Isoproterenol; Lipolysis; Male; Middle Aged; Neprilysin; Receptors, Angiotensin; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2011 |
Valsartan, an angiotensin II receptor blocker, attenuates cardiac dysfunction and oxidative stress in isoproterenol-induced cardiotoxicity.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cardiotonic Agents; Cardiotoxins; Heart Diseases; Heart Rate; Isoproterenol; Male; Oxidative Stress; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2011 |
Antioxidant and cardioprotective effects of Danshensu (3-(3, 4-dihydroxyphenyl)-2-hydroxy-propanoic acid from Salvia miltiorrhiza) on isoproterenol-induced myocardial hypertrophy in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Arrhythmias, Cardiac; Cardiomegaly; Cardiotonic Agents; Connexins; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Electrocardiography; Hemodynamics; Isoproterenol; Lactates; Male; Phytotherapy; Rats; Rats, Sprague-Dawley; Salvia miltiorrhiza; Tetrazoles; Valine; Valsartan | 2011 |
Comparing effects of lacidipine, ramipril, and valsartan against experimentally induced myocardial infarcted rats.
Topics: Administration, Oral; Animals; Cardiotonic Agents; Dihydropyridines; Dose-Response Relationship, Drug; Isoproterenol; Male; Myocardial Infarction; Ramipril; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2012 |
Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection.
Topics: Animals; Blotting, Western; Cardiomegaly; Cardiotonic Agents; Cell Line; Cytokines; Disease Models, Animal; Down-Regulation; Heart Failure; Isoproterenol; Male; Myocytes, Cardiac; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Valine; Valsartan | 2013 |
Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aminobutyrates; Animals; Antihypertensive Agents; Antioxidants; Aspartate Aminotransferases; Biphenyl Compounds; Catalase; Creatine Kinase, MB Form; Drug Combinations; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Isoproterenol; Lactate Dehydrogenases; Male; Malondialdehyde; Myocardial Infarction; Myocardium; Neprilysin; Oxidative Stress; Rats; Rats, Wistar; Superoxide Dismutase; Tetrazoles; Valsartan | 2019 |
Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Fibrosis; Hemodynamics; Humans; Hypertrophy, Left Ventricular; Isoproterenol; Myocardium; Neprilysin; Protease Inhibitors; Rats, Wistar; Tetrazoles; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2019 |
The Protective Effects of Compound 21 and Valsartan in Isoproterenol-Induced Myocardial Injury in Rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Drug Therapy, Combination; Heart Failure; Heart Rate; Isoproterenol; Male; Myocardium; Rats, Wistar; Receptor, Angiotensin, Type 2; Stroke Volume; Sulfonamides; Thiophenes; Valsartan; Ventricular Function, Left | 2021 |
Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline-induced takotsubo-like syndrome.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Drug Combinations; Humans; Isoproterenol; Male; Rats; Rats, Sprague-Dawley; Valsartan | 2021 |
Valsartan Regulates PI3K/AKT Pathways through lncRNA GASL1 to Improve Isoproterenol-Induced Heart Failure.
Topics: Animals; Apoptosis; Carrier Proteins; Heart Failure; Humans; Isoproterenol; Male; Myocardium; Myocytes, Cardiac; Rats; RNA, Long Noncoding; Signal Transduction; Valsartan | 2022 |
Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach.
Topics: Antioxidants; Calcium; Collagen; Heart Failure; Hemodynamics; Humans; Isoproterenol; Myocardial Infarction; Ramipril; Simendan; Valsartan | 2023 |